HC Wainwright Predicts Inozyme Pharma Q1 Earnings

Inozyme Pharma, Inc. (NASDAQ:INZY) – Analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Inozyme Pharma in a research report issued on Friday, January 10th. HC Wainwright analyst E. White anticipates that the company will post earnings of ($0.43) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Inozyme Pharma’s current full-year earnings is ($1.59) per share. HC Wainwright also issued estimates for Inozyme Pharma’s Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.44) EPS and Q4 2025 earnings at ($0.50) EPS.

Inozyme Pharma (NASDAQ:INZY) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.05.

Several other analysts have also recently weighed in on INZY. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price objective on shares of Inozyme Pharma in a research report on Wednesday, November 6th. Piper Sandler dropped their price target on Inozyme Pharma from $43.00 to $30.00 and set an “overweight” rating on the stock in a research report on Monday. Wedbush reissued an “outperform” rating and issued a $12.00 target price on shares of Inozyme Pharma in a research note on Friday, January 10th. Wells Fargo & Company dropped their price target on shares of Inozyme Pharma from $14.00 to $11.00 and set an “overweight” rating on the stock in a research note on Monday. Finally, Raymond James assumed coverage on shares of Inozyme Pharma in a report on Thursday, December 12th. They issued an “outperform” rating and a $26.00 target price for the company. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $18.33.

Inozyme Pharma Stock Down 12.2 %

Shares of NASDAQ INZY opened at $1.51 on Monday. The firm has a fifty day simple moving average of $2.91 and a two-hundred day simple moving average of $4.34. Inozyme Pharma has a 12 month low of $1.45 and a 12 month high of $7.80. The company has a current ratio of 7.68, a quick ratio of 7.68 and a debt-to-equity ratio of 0.51. The firm has a market capitalization of $97.00 million, a PE ratio of -0.97 and a beta of 1.35.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Bank of New York Mellon Corp lifted its position in shares of Inozyme Pharma by 16.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 190,896 shares of the company’s stock valued at $851,000 after buying an additional 26,464 shares in the last quarter. Rhumbline Advisers increased its stake in Inozyme Pharma by 22.0% in the 2nd quarter. Rhumbline Advisers now owns 77,004 shares of the company’s stock worth $343,000 after buying an additional 13,867 shares in the last quarter. American Century Companies Inc. lifted its position in shares of Inozyme Pharma by 11.0% in the second quarter. American Century Companies Inc. now owns 57,100 shares of the company’s stock valued at $255,000 after acquiring an additional 5,673 shares in the last quarter. Meeder Asset Management Inc. purchased a new stake in shares of Inozyme Pharma during the second quarter worth about $68,000. Finally, Dimensional Fund Advisors LP raised its stake in Inozyme Pharma by 117.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 380,064 shares of the company’s stock valued at $1,695,000 after purchasing an additional 205,417 shares during the period. Hedge funds and other institutional investors own 88.30% of the company’s stock.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.